Staphylokinase during stroke blood-flow treatment
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial studies using a medication called non-immunogenic staphylokinase as part of standard clot-busting treatment for an acute ischemic stroke. It may help clinicians improve blood flow after the stroke using an approach designed to be less likely to trigger immune reactions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 85 years old.
- Have an acute ischemic stroke and be eligible for clot-busting (thrombolytic) treatment.
- You are planning to receive non-immunogenic staphylokinase as the clot-busting medicine, or you already received it.
- You have no known severe allergy or intolerance to staphylokinase or similar recombinant protein medicines.
- You must not have any reason you cannot receive clot-busting treatment (thrombolytic therapy contraindication).
- You are not pregnant and not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an investigational study drug can improve outcomes after an acute ischemic stroke (a stroke caused by blocked blood flow). You may be eligible if you are able to start treatment quickly after symptom onset and have a moderate stroke severity on a standard stroke exam.
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
This trial tests whether adding a medicine called human urinary kallidinogenase (which improves blood flow to the brain) to standard clot-busting treatment (reteplase) helps people recover better from an acute stroke. It's for patients who arrive at the hospital within 4.5 hours of symptom onset and meet specific safety criteria.
This trial tests whether a drug called urinary kallidinogenase can help people who have had a stroke caused by a blocked artery in the brain. The drug is given within 48 hours of the stroke, and the study hopes to see if it improves recovery and reduces disability.
This trial tests whether adding a low dose of a clot-busting medicine to the standard emergency procedure to open blocked heart arteries can improve outcomes for people having a heart attack. It aims to see if the combination is safe and more effective than the standard procedure alone.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
Hear when a new Acute Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.